Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Revelation Biosciences Inc (NQ: REVB )

1.650 +0.090 (+5.77%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,031
Open 1.560
Bid (Size) 1.620 (11)
Ask (Size) 1.680 (1)
Prev. Close 1.560
Today's Range 1.560 - 1.680
52wk Range 0.2770 - 25.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met its primary endpoint and identified a maximum tolerated dose. 
Via Benzinga
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
From Revelation Biosciences, Inc.
Via Business Wire

Performance

YTD
+223.53%
+223.53%
1 Month
-11.76%
-11.76%
3 Month
-23.26%
-23.26%
6 Month
-81.25%
-81.25%
1 Year
+96.50%
+96.50%

More News

Read More
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
Via InvestorPlace
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
Top 5 Health Care Stocks That Are Preparing To Pump In February
Via Benzinga
BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
From Revelation Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Meta Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Dow Jumps 250 Points; Honeywell Issues Weak Forecast
Via Benzinga
Topics Stocks
Exposures US Equities
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.